Rhythm Pharmaceuticals (FRA:1RV) LT-Debt-to-Total-Asset : 0.00 (As of Mar. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Rhythm Pharmaceuticals LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Rhythm Pharmaceuticals's long-term debt to total assests ratio for the quarter that ended in Mar. 2024 was 0.00.

Rhythm Pharmaceuticals's long-term debt to total assets ratio declined from Mar. 2023 (0.00) to Mar. 2024 (0.00). It may suggest that Rhythm Pharmaceuticals is progressively becoming less dependent on debt to grow their business.

Rhythm Pharmaceuticals LT-Debt-to-Total-Asset Historical Data

The historical data trend for Rhythm Pharmaceuticals's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rhythm Pharmaceuticals LT-Debt-to-Total-Asset Chart

Rhythm Pharmaceuticals Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.01

Rhythm Pharmaceuticals Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															-	-	-	-	-

Rhythm Pharmaceuticals LT-Debt-to-Total-Asset Calculation

Rhythm Pharmaceuticals's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )	/	Total Assets (A: Dec. 2023 )
	=	0.449	/	305.127
	=	0.00

Rhythm Pharmaceuticals's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2024 is calculated as

LT Debt to Total Assets (Q: Mar. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Mar. 2024 )	/	Total Assets (Q: Mar. 2024 )
	=	0.261	/	237.959
	=	0.00

Rhythm Pharmaceuticals (FRA:1RV) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Rhythm Pharmaceuticals LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Rhythm Pharmaceuticals's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Rhythm Pharmaceuticals (FRA:1RV) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Rhythm Pharmaceuticals Inc (FRA:1RV) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

RYTM:USA RYTM:Mexico 1RV:Germany

Address

222 Berkeley Street, 12th Floor, Boston, MA, USA, 02116

Website

http://www.rhythmtx.com

Rhythm Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in development and commercialization of therapies for patients with rare diseases. It is focused on the development and commercialization of peptide therapeutics for the treatment of gastrointestinal, or GI, diseases, and genetic deficiencies that result in metabolic disorders. The company's product candidate is setmelanotide (RM 493), which is a potent, melanocortin 4, or MC4, receptor agonist for the treatment of rare genetic disorders of obesity caused by MC4 pathway deficiencies.

Rhythm Pharmaceuticals (FRA:1RV) Headlines

No Headlines